Literature DB >> 1360199

Hypofrontality in neuroleptic-naive patients and in patients with chronic schizophrenia. Assessment with xenon 133 single-photon emission computed tomography and the Tower of London.

N C Andreasen1, K Rezai, R Alliger, V W Swayze, M Flaum, P Kirchner, G Cohen, D S O'Leary.   

Abstract

The "hypofrontality hypothesis" has been supported by many neuroimaging studies, but not all, perhaps because of heterogeneity of samples. The present study examined three different samples that permitted assessment of a variety of confounders, such as effects of long-term treatment, chronicity of illness, and presenting phenomenology: (1) 13 neuroleptic-naive schizophrenic patients, (2) 23 nonnaive schizophrenic patients who had been relatively chronically ill but were medication free for at least 3 weeks, and (3) 15 healthy normal volunteers. Regional cerebral blood flow was measured using single-photon emission computed tomography with xenon 133 as the tracer. The control condition consisted of looking at undulating colored shapes on a video monitor, while the experimental task was the Tower of London. We observed the Tower of London to be a relatively specific stimulant of the left mesial frontal cortex (probably including parts of the cingulate gyrus) in healthy normal volunteers. Both the neuroleptic-naive and the nonnaive patients lacked this area of activation, as well as a related one in the right parietal cortex (representing the circuitry specifically activated by the Tower of London). Decreased activation occurred only in the patients with high scores for negative symptoms. These results suggest that hypofrontality is related to negative symptoms and is not a long-term effect of neuroleptic treatment or of chronicity of illness.

Entities:  

Mesh:

Substances:

Year:  1992        PMID: 1360199     DOI: 10.1001/archpsyc.1992.01820120031006

Source DB:  PubMed          Journal:  Arch Gen Psychiatry        ISSN: 0003-990X


  92 in total

1.  Gene expression profiling reveals alterations of specific metabolic pathways in schizophrenia.

Authors:  Frank A Middleton; Karoly Mirnics; Joseph N Pierri; David A Lewis; Pat Levitt
Journal:  J Neurosci       Date:  2002-04-01       Impact factor: 6.167

Review 2.  [Genetic and pharmacological effects on prefrontal cortical function in schizophrenia].

Authors:  Andreas Heinz; Dieter F Braus; Berenice Romero; Jürgen Gallinat; Imke Puls; Georg Juckel; Daniel R Weinberger
Journal:  Nervenarzt       Date:  2004-09       Impact factor: 1.214

3.  Resting quantitative cerebral blood flow in schizophrenia measured by pulsed arterial spin labeling perfusion MRI.

Authors:  Amy Pinkham; James Loughead; Kosha Ruparel; Wen-Chau Wu; Eve Overton; Raquel Gur; Ruben Gur
Journal:  Psychiatry Res       Date:  2011-08-09       Impact factor: 3.222

Review 4.  Neuroimaging of cognitive disability in schizophrenia: search for a pathophysiological mechanism.

Authors:  J D Ragland; J Yoon; M J Minzenberg; C S Carter
Journal:  Int Rev Psychiatry       Date:  2007-08

5.  Functional MR study of a motor task and the tower of London task at 1.0 T.

Authors:  A Boghi; O Rampado; M Bergui; F Avidano; C Manzone; M Coriasco; P Mortara; L Orsi; R Ropolo; G B Bradac
Journal:  Neuroradiology       Date:  2006-08-30       Impact factor: 2.804

6.  Comparison of Classical and Clozapine Treatment on Schizophrenia Using Positive and Negative Syndrome Scale of Schizophrenia (PANSS) and SPECT Imaging.

Authors:  Mohammad Sharafi
Journal:  Int J Med Sci       Date:  2005-05-10       Impact factor: 3.738

7.  Dissociation of acute and chronic intermittent phencyclidine-induced performance deficits in the 5-choice serial reaction time task: influence of clozapine.

Authors:  David M Thomson; Allan McVie; Brian J Morris; Judith A Pratt
Journal:  Psychopharmacology (Berl)       Date:  2010-09-29       Impact factor: 4.530

8.  Effect of schizophrenia on frontotemporal activity during word encoding and recognition: a PET cerebral blood flow study.

Authors:  J D Ragland; R C Gur; J Raz; L Schroeder; C G Kohler; R J Smith; A Alavi; R E Gur
Journal:  Am J Psychiatry       Date:  2001-07       Impact factor: 18.112

Review 9.  Peripheral biomarkers revisited: integrative profiling of peripheral samples for psychiatric research.

Authors:  Akiko Hayashi-Takagi; Marquis P Vawter; Kazuya Iwamoto
Journal:  Biol Psychiatry       Date:  2013-10-18       Impact factor: 13.382

Review 10.  Cell and receptor type-specific alterations in markers of GABA neurotransmission in the prefrontal cortex of subjects with schizophrenia.

Authors:  David A Lewis; Takanori Hashimoto; Harvey M Morris
Journal:  Neurotox Res       Date:  2008-10       Impact factor: 3.911

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.